Skip to content

Pethidine Analgesia on Labor Duration

The Effect of Pethidine Analgesia on Labor Duration and Maternal-Fetal Outcomes

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03882814
Enrollment
240
Registered
2019-03-20
Start date
2017-07-01
Completion date
2018-06-01
Last updated
2020-10-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Labor Pain

Keywords

Analgesia, labor, pethidine, Active Phase

Brief summary

Although opioid analgesics are used to treat labor pain, there are still concerns about their side effects. The researchers in this study; aimed to evaluate the effect of pethidine on active phase duration of labor, labor pain and maternal-neonatal. 50 mg pethidine will be administered intramuscularly to the cases to be included in the study group. The patients in the control group will be given placebo injections. Vital signs of all cases included in the study will be checked at 0, 5, 15, 30, 45 and 60 minutes. Pain will also be assessed by Visual Analogue Scale (VAS) before injection and at the 1st and 2nd hour after injection. Delivery times, maternal side effects, neonatal apgar scores and fetal findings will be recorded.

Interventions

DRUGpethidine

Pethidine 50 mg intramuscular (IM) injection was performed when cervical dilatation was at or greater than 4 cm and the cardiotocogram uterine contraction recordings of 200 Montevideo units was reached. Opioid analgesia (pethidine HCl - 50 mg I.M.) was given following amniotomy.

Intramuscular saline was administered to the control group as placebo. Salin intramuscular (IM) injection was performed when cervical dilatation was at or greater than 4 cm and the cardiotocogram uterine contraction recordings of 200 Montevideo units was reached. salon was given following amniotomy.

Sponsors

Gaziosmanpasa Research and Education Hospital
CollaboratorOTHER_GOV
Kanuni Sultan Suleyman Training and Research Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 40 Years
Healthy volunteers
No

Inclusion criteria

* nullipar-multiparous patients; * singleton pregnancies 37- 41 weeks (by the last menstrual period).

Exclusion criteria

* maternal respiratory rate \< 8 /min, * maternal bradycardia (\<60 bpm), * major fetal congenital anomalies, * uterine scar presence from previous pregnancies, * malpresentation, * antepartum hemorrhage, * multiple pregnancy, * labor induction, * chronic systemic disease, * rupture fetal membranes, * epidural analgesia.

Design outcomes

Primary

MeasureTime frameDescription
Active phase of labor with pethidineduring laborThe study group that accepted pethidine injection comprised of 132 patients; The active phase duration was evaluated in minutes.
Labor pain with pethidineduring laborLabor pain VAS scores were determined in both groups just prior to pethidine injection (0.hour), and 1st and 2nd hours after injection. The VAS scale represents pain with a score of 1 to 10. patients scored points on this scale and these scores were recorded. 1 point shows the least pain, 10 points the most-irresistible pain.

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026